Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › ERIS

ERIS

Eris Lifesciences Limited
Small-capPharma ↗

What the six lenses say about ERIS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1430.0
2026-07-10
VWAP · 1Y anchor
₹1559
-8.3% from VWAP
P/E · TTM
31.7×
TTM EPS ₹45.1
52-week range
29%
position low→high
RSI(14)
52
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How ERIS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD550›

The actual numbers

Price vs VWAP (1y)-8.3%
EMA trend stackMixed
Price vs 200-EMA-0.5%
Price vs 50-EMA+1.8%
RSI(14)52
RS vs Nifty 500 · 3M+1.0%
RS vs sector · 3M-11.5%
52-week range29%
Volume vs 30d avg1.47×
Volume vs 60d avg0.78×
ATR(14) · volatility41.0
Bollinger width · vol contraction0.067
FundamentalD764›

The actual numbers

Return on equity (ROE)18.7%
Return on capital (ROCE)14.1%
Operating margin26.6%
Net margin20.7%
Revenue growth · YoY+8.2%
EPS growth · YoY+74.4%
Debt / equity0.60×

Full 8-quarter history in the financials table below.

ValuationD637›

The actual numbers

P/E (TTM)31.7×
TTM EPS₹45.1
52-week range29%
CatalystD538›

The actual numbers

Earnings & momentum42
Capital actions8
Governance86

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding53.9%
Delivery · 30d avg55.0%
Up/down-day asymmetry-1.7pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D5 + D6 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Medium
50
Conviction score 50/100 · avg-decile strength 5.5/10
Conviction score50/100›
TechnicalD5›
FundamentalD7›
ValuationD6›
CatalystD5›
FlowD6›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.7pp
-0.4pp
+1.4pp
+4.6pp
+1.5pp
-12.5pp
Nifty 500
Broad-market baseline
+0.2pp
-0.5pp
+0.8pp
+1.0pp
-3.6pp
-16.3pp
Sector
Own-sector index
—
—
-1.6pp
-11.5pp
-17.9pp
-34.2pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ERIS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1430.00+14.00

Relative strength

RS vs baseline · rebased to 100

ERIS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
137.39+0.32

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)720739727705773792807757
↳ change QoQ—+2.7%-1.6%-3.1%+9.6%+2.5%+1.9%-6.2%
EBITDA (₹cr)252269255252277288282272
EBITDA margin35.0%36.4%35.0%35.7%35.8%36.4%34.9%35.9%
PAT (₹cr)899687102125134109279
↳ change QoQ—+7.8%-9.8%+17.3%+22.5%+7.2%-18.7%+156.0%
Net margin12.4%13.0%11.9%14.5%16.2%16.9%13.5%36.9%
EPS (₹)6.116.736.156.898.668.827.3220.33
D/E————————
YoY growth · Mar '26Revenue +7.4% YoYPAT +173.5% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 8 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 May '26
    LOWgovernance
    Action(s) taken or orders passed
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 May '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 20 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 15 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 May '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 May '26
    LOWgovernance
    ESOP/ESOS/ESPS
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 May '26
    MEDIUMcapital
    Credit Rating
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 20 Apr '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Mar '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 Mar '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds ERIS

Mutual funds holding ERIS (10)

FundWeightAUM ₹crGrade
HDFC Small Cap Gr2.37%38,809
Franklin India Flexi Cap Gr1.05%18,797
DSP Small Cap Reg Gr0.94%18,358
HSBC Small Cap Fund Reg Gr0.64%16,877
Franklin India Small Cap Gr2.26%13,847
UTI Mid Cap Reg Gr0.81%12,122
Franklin India ELSS Tax Saver Gr1.07%6,039
UTI Small Cap Reg Gr1.51%5,213
Franklin India Multi Cap Reg Gr1.49%4,892
Mirae Asset Healthcare Reg Gr3.25%3,091

ETFs holding ERIS (2)

ETFWeightGrade
Mirae Asset Nifty 500 Healthcare ETF0.61%
Motilal Oswal BSE Healthcare ETF0.58%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma